Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Business Insights | The US Pharmaceutical Market Outlook To 2014: Market trends, leading players and forecasts

The US Pharmaceutical Market Outlook To 2014: Market trends, leading players and forecasts

The US healthcare system involves a multitude of stakeholders; a mix of public and private players. The government funds healthcare for certain sections of the society while majority of the population has a private health insurance sponsored by employers. Pharmaceutical manufacturers in the US are relatively free to set their own prices for drugs which tend to be, on an average, two to three times higher than in Europe. The US market in general works by administering reimbursement controls rather than price controls. Instead of a direct price control, the government is known to have been using tacit persuasion tactics, on grounds of morality, to convince drug companies to slash prices. However the scenario is changing in light of a growing demand for administering direct price controls. The report provides analysis on the performance of key brands in a range of major indications in the US pharmaceutical market, including central nervous system disorders, cancer, cardiovascular diseases and metabolic disorders. The report also incorporates analysis of the portfolios and pipelines of the leading pharmaceutical companies active in the US market today.

Published: June 2009 - US.

Table of Contents
Price: $3,835.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions